Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LJM716 plus trastuzumab dose-escalation study in HER2-overexpressing metastatic breast or gastric cancer
NL-OMON37081Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of elgemtumab and trastuzumab in breast cancer, gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Novartis. Primary endpoint: Incidence of dose-limiting toxicities. Started Jun 2013; status: active, not recruiting.
02
Drugs
elgemtumabtrastuzumab
03
Conditions
breast cancergastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON37081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37081.